Cryonics Research

Step into a world of cutting-edge tools and possibilities. Here's a glimpse of the equipment that powers our vision:

• Shaking Incubator with Temperature Control (4 to 40°C): Supports experiments requiring both temperature regulation and agitation.

• Incubators with Temperature and CO2 Control: Ideal for maintaining optimal environments for cellular growth.

• Viking Thermostat Bath: For temperature-controlled experiments requiring consistency.

• 4°C Refrigerator: Ensures safe storage of sensitive materials at stable temperatures.

• Centrifuge: A refrigerated centrifuge to handle sensitive materials with precision.

• Direct Microscopes: For detailed observation of cell structures and biological samples.

• Inverted Microscopes: Specialized for studying cell cultures and advanced research.

• Liquid Nitrogen Thermos: For cryogenic applications, providing a critical tool for advanced preservation techniques.

• Ultra-Low Freezers (-20°C): Ideal for medium-term storage of experimental materials.

• Ultra-Low Freezers (-80°C): Guardians of the cold, ensuring the safe preservation of our samples.

• Ultra-Low Freezers (-125°C): Venturing even deeper into subzero temperatures, providing the highest level of preservation.

  
  

While we have over 400 square meters of space awaiting approval for the development of state-of-the-art cryonics facilities, this equipment serves as the initial foundation for our experiments. We are actively building towards the future, ready to expand and innovate. For now, the tools are ready, the vision is clear, and the possibilities are limitless.

Our Research Arsenal: Ready to Push Boundaries

We have already developed the theoretical prototype necessary to implement this technology, marking a pivotal step in bridging cutting-edge research with practical applications.

Our Technical Proposal Surpasses Current Standards
Our research sets a new standard for preserving patients in the best possible conditions. Our technical proposal is superior, anticipating improved results in cryopreservation. With this strategy, we aim to optimize process efficiency and prolong preservation more effectively.

Prototyping for Implementation

Due to the lack of authorization for procedures without a clinical death declaration, some minimal ischemic damage is inevitable under current legal terms. This implies that some pre-mortem ischemic damage will always occur, but the most significant damage happens post-mortem. Therefore, reducing the time between the declaration of clinical death and the initiation of procedures to an absolute minimum is critical to reducing patient harm.
Immediate resumption of circulation post-mortem benefits tissues by reducing free radical production and reperfusion damage. The integrity of blood vessels is vital for transporting cryoprotectant vitrification solutions to the brain, preventing ice formation. In the future, nanotechnology could address potential brain damage.

Legal state today

We are preparing to publish a legal paper in the coming weeks, laying the groundwork for the potential future acceptance and regulation of cryonics in Argentina.

Changing the game

Safety
Cryonic tubes, an essential component of our process, do not rely on electrical power for maintenance, ensuring their protection and physical integrity at all times. At 1mPossible, your safety is our highest priority. We not only preserve your integrity but also guarantee the continuity of treatments in the face of any eventuality, whether a system failure or a natural disaster. In every step we take and every decision we make, your safety and well-being are central considerations. With 1mPossible, your future is safeguarded in an environment that prioritizes security and the continuity of life.

You are not dead when your heart stops beating and you stop breathing
Death is currently associated with the loss of brain functions. However, it should be redefined as the absolute and definitive irreversible loss of life, occurring only when brain structure is destroyed.
In the medical field, death is commonly associated with the irreversible cessation of brain functions. However, in our research and analysis, we approach cryonics with an innovative perspective, viewing "clinical death" as a metabolic pause, not a point of no return. This approach, supported by emerging technologies such as nanotechnology, offers the potential for reanimation.
Cryonics scientists are legally required to wait for a declaration of clinical death, delaying the initiation of procedures. It is crucial to understand that cryonics aims to preserve lives, not to revive those who are already dead. This legal wait has minimal impact on the effective preservation of the patient's life.
Cryonics theoretically enables the preservation of a human body at extremely low temperatures, with the potential for future revival. While this has not yet been successfully achieved in humans, vitrification methods are being explored to maintain neuronal structures, the foundation of the human mind, intact.
Damage from halting blood flow for six minutes or more primarily affects blood vessels rather than neurons. Cryonics addresses this challenge by suggesting that procedures begin as early as possible, ideally within the first minute of clinical death. However, the method remains viable even if initiated later due to legal restrictions.

Standard Technical Procedure
Following legal death, the patient is submerged in an ice water bath to accelerate cooling. Mechanical cardiopulmonary support is applied to facilitate this process. Rapid water circulation cools the body from 37°C to 10°C. Subsequently, blood and most water are replaced with a cryoprotectant to prevent ice formation. Finally, the body is cooled to -120°C and then to -196°C using liquid nitrogen for storage.
Cryoprotection, using compounds such as glycerol, reduces or eliminates ice formation, preventing structural damage. Intracellular and extracellular crystallization is avoided, minimizing cellular damage. Vitrification, unlike freezing, halts biological time without causing structural harm.

Biology in Ischemia
We have previously explored damage to blood vessels and neurons, both caused by ischemia, which results from a lack of blood flow. "Warm ischemia" occurs when cardiac arrest happens under normal conditions and temperatures at the time of legal death, without immediate cooling. "Cold ischemia" occurs when the patient remains on ice for longer than expected without the application of a cryoprotectant, leading to vascular damage, local edema, and dysfunctional blood vessels.

Clinical Death Is Not Death
Contrary to common belief, our research reveals that the six minutes following cardiac arrest are not determinant for neurological damage. While brain apoptosis begins within this period, the process takes hours to complete, preserving most brain cells. Ischemic damage can be mitigated through stem cell transplantation, increasing ischemic tolerance. Ideally, procedures should begin within two minutes of clinical death declaration and not exceed 15 minutes. Body cooling is crucial to avoid ischemic damage.
Temperature reduction induces hypothermia, suppressing protease activity and protecting the blood-brain barrier. This is essential to prevent brain parenchyma exposure to blood flow and subsequent deterioration.

Reanimation Achieved Using Higher Temperatures in Animals
Experiments on rats, cats, and dogs have demonstrated successful reanimation rates using cooling techniques and blood substitutes. Rats have even been reanimated multiple times, showcasing the process's viability. Experiments on dogs have shown resistance to ischemia, and hypothermia has yielded positive results without significant neurological deterioration. In humans, hypothermic cardiac arrest has been successfully performed during surgical procedures, supporting the effectiveness of similar approaches.

Patient Status
The patient is not truly dead but rather in a state of metabolic suspension with fully intact structures. The lack of appropriate legislation allowing cryonics within the legal framework leads to the declaration of clinical death as a practical solution. Governments are urged to enact laws that enable the immediate implementation of cryonics and redefine the patient's legal status.

Understand the Patient Journey